TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Shared Decision Making Process Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in HbA1c from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Viral antigen/antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cellular and humoral immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Appropriate initial decision about AcipHex selection
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to key directions for use
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Experience of serious / non-serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: post-RT cardiovascular effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary mineralocorticoid receptor-regulated mRNA biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration of drug in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mirror-tracing Persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosage of cardiac biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in perfusion index (PI) at 6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in transcutaneous carbon monoxide (TCO) at 6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal Bioelectrical Impedance Analysis (BIA) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Numeric scale of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Numerical Rating Scale for Average Itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate to vigorous physical activity (objective)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate to vigorous physical activity (subjective)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With >= Grade 3 Laboratory Results
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Chemotherapy Side Effects
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Failure rate of breast reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sum of skin fold thicknesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of continuous glucose monitoring system (CGMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Dose-intensity limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain and function on the Patient-Rated Wrist Evaluation (PRWE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-free overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Fractional Flow Reserve computed tomography (FFRct)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of clinical crown length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of Urethral Stricture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patients' assessment of gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change score on MADRS scale at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Group differences on HRS-D scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Group differences on remission and improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Blood Plasma Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recommended Phase II Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery (QoR15)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Opioid consumption postoperative
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Corneal Epithelial Dye Diffusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Success According to the PGA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Identifying Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Sino-Nasal Outcome Test-20 (SNOT-20)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Protein concentration in exhaled breath particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of stress urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Systemic exposure to topical MRE0094 measured by plasma concentrations of MRE0094
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, intensity, and seriousness of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in irritation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of COPD-related exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in gene expression in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net-ultrafiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Change in Trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oral Health Impact Profile
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Helkimo's anamnestic dysfunction index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Helkimo's clinical dysfunction index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of sizing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to plan/perform case
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incidence of recurrence of fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serum levels of p-cresol and indole derivatives
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Spasticity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of multi-drug resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety measured by number of subjects experiencing SAEs, deaths, AEs leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability measured by number of subjects experiencing SAEs, deaths, AEs leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Safety measured by percent of subjects experiencing SAEs, deaths, AEs leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability measured by percent of subjects experiencing SAEs, deaths, AEs leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: metabolic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: endocrine markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participants With Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: liver function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lipid panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sex-hormone binding globulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: endometrial stripe thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Presence or absence of atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of Willingness to Take PrEP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: recovery rate of bladder function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Average infusion flow rate (mL/hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of wrinkle severity system scale (WSRS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of serious treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment-emergent laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: SNIF test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in transferrin saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With HCV RNA (Early Virological Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Early Virological Response (EVR) and Significant Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without evidence of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of PE during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Rate of response to cabazitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rewarding Events Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mental Health status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Glycaemic Response measured by incremental Area Under the Curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Massachusetts General Hospital Hair Pulling Scale (MGH-HPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of obstructive coronary disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants That Successfully Insert Vaginal Film
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: earlier diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment plan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Children's Depression Inventory-2 (CDI-2) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients with adverse events of grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: haemoglobin concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Acute Kidney Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: stroke or other cerebrovascular symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma glucose incremental area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Crossmatch conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: superior mesenteric (SMA) blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in morphologic, chromatographic and spectrometric scores at week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in morphologic, chromatographic and spectrometric scores at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in morphologic, chromatographic and spectrometric scores at week 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological response at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of ABBV-744
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Tmax) of ABBV-744
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration (AUCt) of ABBV-744
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Recovery 15 (QoR-15) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Hemoglobin A-1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tendon pathology as indicated by sonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient-Rated Global Change Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Insulin Sensitivity From Oral Glucose Tolerance Test (OGTT_SI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinically significant changes in clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in physical examinations, vital signs, and electrocardiograms (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant Stability Quotient (ISQ) Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-Mental Status Exam (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Autism Spectrum Quotient Exam
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Abundance Change of proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance Change of RNA/Genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in patient-reported symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants with Horner's syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MLK endoscopic grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of motion sickness
Endpoint domain: Adverse events/effects
Primary endpoint: cognitive adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmed Response Rate (Complete and Partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Health Assessment Questionnaire at 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in Health Anxiety and Depression Scale at 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Biopsychosocial Exercise Therapy Questionnaire (BETY-BQ) at 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Depression, Anxiety, and Stress Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to bone union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Symptom construct of the R-QOL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serotonin pathway parameters concentrations in blood and urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serotonin pathway parameters concentrations in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Kynurenin pathway parameters concentrations in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Functional Near-Infrared Spectroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Muscle Stiffness using the MyotonPro
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Episode-Free Days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Immune-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in minimum rim width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue oxygenation in the lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Symptoms of Otitis Media
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety levels as measured by the Spence Children's Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: therapeutic effects on erectile dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of Participants Achieving ≥5*10^6 CD34+ Cells/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nadir Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of inappropriate PPI prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Curve from 0 to 24 hours (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration 24 hours after instillation (C24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Functional reach Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pupil area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SAB-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of complete surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain Assessment: Overall
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Measure of Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with reinfection
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality rate among children under-five
Endpoint domain: Mortality/survival
Primary endpoint: Inflammation in the rectosigmoid epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pulmonary and extrapulmonary complications
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in brain structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time in acceptable breathing range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Concentration of chemokines in blood or urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Vitamin D status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With Observed Local Erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Subjects With Observed Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Brigham Spinal Stenosis Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cardiovascular health metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of Idracare® in treating symptoms of vulvovaginal atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood bacterial 16s rDNA bacterial gene concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes